Limits...
The efficacy and safety of irreversible electroporation for the ablation of renal masses: a prospective, human, in-vivo study protocol.

Wagstaff PG, de Bruin DM, Zondervan PJ, Savci Heijink CD, Engelbrecht MR, van Delden OM, van Leeuwen TG, Wijkstra H, de la Rosette JJ, Laguna Pes MP - BMC Cancer (2015)

Bottom Line: Electroporation is a novel treatment technique utilizing electric pulses, traveling between two or more electrodes, to ablate targeted tissue.Before progressing to a long-term IRE follow-up study it is vital to have pathological confirmation of the efficacy of the technique.MRI and CEUS imaging will be performed at baseline, one week and four weeks post IRE.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Academic Medical Center, Meibergdreef 9, 1105AZ, Amsterdam, Netherlands. p.g.wagstaff@amc.nl.

ABSTRACT

Background: Electroporation is a novel treatment technique utilizing electric pulses, traveling between two or more electrodes, to ablate targeted tissue. The first in human studies have proven the safety of IRE for the ablation of renal masses. However the efficacy of IRE through histopathological examination of an ablated renal tumour has not yet been studied. Before progressing to a long-term IRE follow-up study it is vital to have pathological confirmation of the efficacy of the technique. Furthermore, follow-up after IRE ablation requires a validated imaging modality. The primary objectives of this study are the safety and the efficacy of IRE ablation of renal masses. The secondary objectives are the efficacy of MRI and CEUS in the imaging of ablation result.

Methods/design: 10 patients, age ≥ 18 years, presenting with a solid enhancing mass, who are candidates for radical nephrectomy will undergo IRE ablation 4 weeks prior to radical nephrectomy. MRI and CEUS imaging will be performed at baseline, one week and four weeks post IRE. After radical nephrectomy, pathological examination will be performed to evaluate IRE ablation success.

Discussion: The only way to truly assess short-term (4 weeks) ablation success is by histopathology of a resection specimen. In our opinion this trial will provide essential knowledge on the safety and efficacy of IRE of renal masses, guiding future research of this promising ablative technique.

Trial registration: Clinicaltrials.gov registration number NCT02298608 . Dutch Central Committee on Research Involving Human Subjects registration number NL44785.018.13.

Show MeSH

Related in: MedlinePlus

IRE equipment. The NanoKnife IRE console (A) utilizes 19G monopolar needle electrodes (B) which can be locked together using external spacers (C).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4376341&req=5

Fig2: IRE equipment. The NanoKnife IRE console (A) utilizes 19G monopolar needle electrodes (B) which can be locked together using external spacers (C).

Mentions: This study utilizes the Angiodynamics (Queensbury, New York) NanoKnife™ IRE device (Figure 2A), also registered as the HVP-01 Electroporation System. This IRE system consists of a Low Energy Direct Current (LEDC) generator, footswitch and 19G monopolar needle electrodes (15 or 25 cm length). The device and electrodes have been developed for soft tissue ablation. Both the device and the electrodes carry a CE certificate for cell membrane electroporation. The system has been approved by the FDA via 510(k) Premarket Notifications (K060054, K080202, K080376, K080287). All 510(k) cleared components are indicated for surgical ablation of soft tissue.Figure 2


The efficacy and safety of irreversible electroporation for the ablation of renal masses: a prospective, human, in-vivo study protocol.

Wagstaff PG, de Bruin DM, Zondervan PJ, Savci Heijink CD, Engelbrecht MR, van Delden OM, van Leeuwen TG, Wijkstra H, de la Rosette JJ, Laguna Pes MP - BMC Cancer (2015)

IRE equipment. The NanoKnife IRE console (A) utilizes 19G monopolar needle electrodes (B) which can be locked together using external spacers (C).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4376341&req=5

Fig2: IRE equipment. The NanoKnife IRE console (A) utilizes 19G monopolar needle electrodes (B) which can be locked together using external spacers (C).
Mentions: This study utilizes the Angiodynamics (Queensbury, New York) NanoKnife™ IRE device (Figure 2A), also registered as the HVP-01 Electroporation System. This IRE system consists of a Low Energy Direct Current (LEDC) generator, footswitch and 19G monopolar needle electrodes (15 or 25 cm length). The device and electrodes have been developed for soft tissue ablation. Both the device and the electrodes carry a CE certificate for cell membrane electroporation. The system has been approved by the FDA via 510(k) Premarket Notifications (K060054, K080202, K080376, K080287). All 510(k) cleared components are indicated for surgical ablation of soft tissue.Figure 2

Bottom Line: Electroporation is a novel treatment technique utilizing electric pulses, traveling between two or more electrodes, to ablate targeted tissue.Before progressing to a long-term IRE follow-up study it is vital to have pathological confirmation of the efficacy of the technique.MRI and CEUS imaging will be performed at baseline, one week and four weeks post IRE.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Academic Medical Center, Meibergdreef 9, 1105AZ, Amsterdam, Netherlands. p.g.wagstaff@amc.nl.

ABSTRACT

Background: Electroporation is a novel treatment technique utilizing electric pulses, traveling between two or more electrodes, to ablate targeted tissue. The first in human studies have proven the safety of IRE for the ablation of renal masses. However the efficacy of IRE through histopathological examination of an ablated renal tumour has not yet been studied. Before progressing to a long-term IRE follow-up study it is vital to have pathological confirmation of the efficacy of the technique. Furthermore, follow-up after IRE ablation requires a validated imaging modality. The primary objectives of this study are the safety and the efficacy of IRE ablation of renal masses. The secondary objectives are the efficacy of MRI and CEUS in the imaging of ablation result.

Methods/design: 10 patients, age ≥ 18 years, presenting with a solid enhancing mass, who are candidates for radical nephrectomy will undergo IRE ablation 4 weeks prior to radical nephrectomy. MRI and CEUS imaging will be performed at baseline, one week and four weeks post IRE. After radical nephrectomy, pathological examination will be performed to evaluate IRE ablation success.

Discussion: The only way to truly assess short-term (4 weeks) ablation success is by histopathology of a resection specimen. In our opinion this trial will provide essential knowledge on the safety and efficacy of IRE of renal masses, guiding future research of this promising ablative technique.

Trial registration: Clinicaltrials.gov registration number NCT02298608 . Dutch Central Committee on Research Involving Human Subjects registration number NL44785.018.13.

Show MeSH
Related in: MedlinePlus